Pt # | Sites of disease | Prior therapy | HER2/neu test | HER2/neu therapy | Concurrent therapy | Duration of therapy | Overall survival | Best response |
---|---|---|---|---|---|---|---|---|
1 | Liver, mediastinum, Lung | Gemcitabine folfirinox | Mutation (NGS) V777L | Trastuzumab | Gemcitabine, docetaxel | 19 | 29 | PD |
2 | Liver, peritoneum, lung | Gemcitabine + cisplatin | ERBB2 amp NGS | Trastuzumab | FOLFOX | 14 | 25 | PD |
3 | Mediastinum | Gemcitabine + cisplatin, FOLFIRI, GTX | ERBB2 NGS S310F | Trastuzumab | FOLFOX | 7 | 7 | PD |
4 | Liver, lung | Nil | AMPLIFIED (FISH) | Trastuzumab | Â | 6 | 8 | PD |
5 | Lung, liver, bones | Gemcitabine + cisplatin | AMPLIFIED (FISH) | Trastuzumab | Â | 10 | 12 | PD |